TARO-IMIPENEM-CILASTATIN 500 MG
IMIPENEM : 500 MG CILASTATIN (CILASTATIN SODIUM) : 500 MG · DIN 02351706 · SUN PHARMA CANADA INC
Health Canada status: MARKETED
What is TARO-IMIPENEM-CILASTATIN?
TARO-IMIPENEM-CILASTATIN 500 MG contains IMIPENEM : 500 MG CILASTATIN (CILASTATIN SODIUM) : 500 MG. It is listed in the Health Canada Drug Product Database under DIN 02351706, held by SUN PHARMA CANADA INC, supplied as POWDER FOR SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 31-May-2021. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is TARO-IMIPENEM-CILASTATIN used for?
TARO - Imipenem - Cilastatin (imipenem and cilastatin for injection) is indicated for the treatment of serious infections caused by sensitive strains of bacteria, including Lower Respiratory Tract Infections, Urinary Tract Infections, Intra-Abdominal Infections, Gynecological Infections, Septicemia, Endocarditis caused by Staphylococcus aureus, Bone and Joint Infections, and Skin Structure Infections. It is not indicated for the treatment of meningitis.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02351706 |
|---|---|
| Brand name | TARO-IMIPENEM-CILASTATIN |
| Generic / active ingredient | IMIPENEM : 500 MG CILASTATIN (CILASTATIN SODIUM) : 500 MG |
| Manufacturer | SUN PHARMA CANADA INC |
| Strength | 500 MG |
| Dosage form | POWDER FOR SOLUTION |
| Route of administration | INTRAVENOUS |
| Schedule | Prescription |
| ATC code | J01DH51 IMIPENEM AND CILASTATIN |
| AHFS class | 08:12.07.08 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 31-May-2021 |
| Original market date | 2010-08-25 00:00:00 |
How is it stored and handled?
null
How is it supplied?
250 mg imipenem and 250 mg cilastatin (as cilastatin sodium) per vial in clear glass 30 mL vials with a blue coloured flip-off seal; 500 mg imipenem and 500 mg cilastatin (as cilastatin sodium) per vial in clear glass 30 mL vials with a red coloured flip-off seal
What can be used instead?
Other Canadian products sharing ATC code J01DH51 IMIPENEM AND CILASTATIN. 2 of 14 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| IMIPENEM AND CILASTATIN FOR INJECTION USP | 500 MG | POWDER FOR SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02358344 |
| IMIPENEM AND CILASTATIN FOR INJECTION | 250 MG | POWDER FOR SOLUTION | PFIZER CANADA ULC | CANCELLED PRE MARKET | DIN 02357429 |
| IMIPENEM AND CILASTATIN FOR INJECTION | 500 MG | POWDER FOR SOLUTION | PFIZER CANADA ULC | CANCELLED POST MARKET | DIN 02357437 |
| IMIPENEM AND CILASTATIN FOR INJECTION USP | 250 MG | POWDER FOR SOLUTION | SANDOZ CANADA INCORPORATED | CANCELLED POST MARKET | DIN 02358336 |
| IMIPENEM AND CILASTATIN FOR INJECTION, USP | 250 MG | POWDER FOR SOLUTION | STERIMAX INC | APPROVED | DIN 02441225 |
| IMIPENEM AND CILASTATIN FOR INJECTION, USP | 250 MG | POWDER FOR SOLUTION | METHAPHARM INC | CANCELLED PRE MARKET | DIN 02439840 |
| IMIPENEM AND CILASTATIN FOR INJECTION, USP | 500 MG | POWDER FOR SOLUTION | STERIMAX INC | APPROVED | DIN 02441233 |
| IMIPENEM AND CILASTATIN FOR INJECTION, USP | 500 MG | POWDER FOR SOLUTION | METHAPHARM INC | CANCELLED PRE MARKET | DIN 02439859 |
| PRIMAXIN 250 | 250 MG | POWDER FOR SOLUTION | MERCK CANADA INC | CANCELLED POST MARKET | DIN 00717274 |
| PRIMAXIN 500 | 500 MG | POWDER FOR SOLUTION | MERCK CANADA INC | CANCELLED POST MARKET | DIN 00717282 |
Who else supplies IMIPENEM AND CILASTATIN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. IMIPENEM AND CILASTATIN appears in 12 registered pack listings across 2 markets, published on 2 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.